A phase 1 trial combines immunotherapy and an oncolytic virus for high-grade neuroendocrine tumors, aiming to enroll 36 patients by 2030. The trial evaluates Opdivo, Yervoy, and Seneca Valley ...

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors. With the recent approval by the U.S. Food and Drug Administration (FDA) of ...

such as C 11-5HTP or Ga 68-DOTA octreotate, will improve staging and follow-up of therapy in patients with neuroendocrine tumors. Somatostatin analogs (e.g., octreotide, lanreotide) will continue ...

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

Consequently, Cabometyx is now the first and only systemic treatment that is FDA-approved for previously treated neuroendocrine tumors regardless of primary tumor site, grade, somatostatin ...

Cabozantinib significantly delayed disease progression in advanced pancreatic and extra-pancreatic neuroendocrine tumors, as shown in the phase 3 CABINET trial. The trial demonstrated a median PFS ...

A recent study in JAMA Internal Medicine reveals that CT scans, while vital for diagnosis, may elevate cancer risk due to radiation exposure. With CT scan usage up 30% since 2007, experts estimate ...

MONDAY, March 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated ...

The approval was based on the results of the phase 3 CABINET study, which compared cabozantinib to a placebo in patients with advanced pancreatic neuroendocrine tumors and advanced extrapancreatic ...